AML Blood Test – A new method for the early detection and prognosis of acute myeloid leukemia

Diagnosing leukemia, especially acute myeloid leukemia (AML), is hindered due to the unspecific symptoms of the disease. Unfortunately misdiagnoses and mistreatments with antiviral or antibiotic medicine lead to a loss of precious time in fighting against this type of cancer.

Scientists from the University of Bonn tackled this challenge by developing a blood test. This test is based on one of the most advanced approaches of gene expression profiling: gene signatures. By adaptive learning and simulation the new blood test for acute myeloid leukemia (AML-BT) was generated. With an “RNA-fingerprint”, the analysis of the different indicator RNAs – showing a decreased or increased expression rate as indication for AML – can be conducted and used for a reliable diagnosis.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Why getting in touch with our ‘gerbil brain’ could help machines listen better

Macquarie University researchers have debunked a 75-year-old theory about how humans determine where sounds are coming from, and it could unlock the secret to creating a next generation of more…

Attosecond core-level spectroscopy reveals real-time molecular dynamics

Chemical reactions are complex mechanisms. Many different dynamical processes are involved, affecting both the electrons and the nucleus of the present atoms. Very often the strongly coupled electron and nuclear…

Free-forming organelles help plants adapt to climate change

Scientists uncover how plants “see” shades of light, temperature. Plants’ ability to sense light and temperature, and their ability to adapt to climate change, hinges on free-forming structures in their…

Partners & Sponsors